Ototoxicity of cis-diamminedichloroplatinum (II)

Influence of dose, schedule and mode of administration

J. B. Vermorken, T. S. Kapteijn, A. A M Hart, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5% and tinnitus in 25% of all patients. The incidence of audiographic changes (65% overall, 81% bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume19
Issue number1
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Cisplatin
Appointments and Schedules
Tinnitus
Incidence
Hearing Loss
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Ototoxicity of cis-diamminedichloroplatinum (II) : Influence of dose, schedule and mode of administration. / Vermorken, J. B.; Kapteijn, T. S.; Hart, A. A M; Pinedo, H. M.

In: European Journal of Cancer and Clinical Oncology, Vol. 19, No. 1, 1983, p. 53-58.

Research output: Contribution to journalArticle

Vermorken, J. B. ; Kapteijn, T. S. ; Hart, A. A M ; Pinedo, H. M. / Ototoxicity of cis-diamminedichloroplatinum (II) : Influence of dose, schedule and mode of administration. In: European Journal of Cancer and Clinical Oncology. 1983 ; Vol. 19, No. 1. pp. 53-58.
@article{184f0df0ffd947059fed9884e9f5ebc5,
title = "Ototoxicity of cis-diamminedichloroplatinum (II): Influence of dose, schedule and mode of administration",
abstract = "During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5{\%} and tinnitus in 25{\%} of all patients. The incidence of audiographic changes (65{\%} overall, 81{\%} bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.",
author = "Vermorken, {J. B.} and Kapteijn, {T. S.} and Hart, {A. A M} and Pinedo, {H. M.}",
year = "1983",
doi = "10.1016/0277-5379(83)90398-X",
language = "English (US)",
volume = "19",
pages = "53--58",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "1",

}

TY - JOUR

T1 - Ototoxicity of cis-diamminedichloroplatinum (II)

T2 - Influence of dose, schedule and mode of administration

AU - Vermorken, J. B.

AU - Kapteijn, T. S.

AU - Hart, A. A M

AU - Pinedo, H. M.

PY - 1983

Y1 - 1983

N2 - During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5% and tinnitus in 25% of all patients. The incidence of audiographic changes (65% overall, 81% bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.

AB - During and after 233 cycles of cis-diamminedichloroplatinum (II) (CDDP), 197 serial audiograms were obtained in 48 patients and compared with baseline audiograms. Use was made of three dose schedules (20 mg/m2, 25-50 mg/m2 and 70-120 mg/m2), two regimens (single-day or daily for 5 days) and three modes of administration (rapid infusion, 2- or 3-hr infusion, 24-hr infusion). Clinical hearing loss occurred in 12.5% and tinnitus in 25% of all patients. The incidence of audiographic changes (65% overall, 81% bilaterally) increased with increasing cumulative CDDP dose independent of treatment schedule. The incidence was correlated with the daily dose (P = 0.0037) and changes were more severe after single high doses. No difference was found between the single low dose and the daily for 5 days regimen. Rapid infusion of a single high dose was more ototoxic than a 24-hr infusion of the same dose (P = 0.0015). It is concluded that, compared with the single high-dose regimen, the daily low dose for 5 days is preferable in cases where the patient might be cured by a regimen including CDDP.

UR - http://www.scopus.com/inward/record.url?scp=0020659723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020659723&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(83)90398-X

DO - 10.1016/0277-5379(83)90398-X

M3 - Article

VL - 19

SP - 53

EP - 58

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 1

ER -